This company has not started trading yet. The live 5-factor QL signal switches on automatically on its first session.
We believe, drawing on our industry experience, market understanding and extensive clinical evidence, that we have created a first-in-category healthcare platform: the first clinically validated treatment for early-stage cavities that helps preserve the natural tooth structure and enables the restoration of enamel crystal density throughout the lesion, in a similar way to how nature built the tooth.
From vVARDIS Holding AG's Form F-1/A filed with the SEC on 2026-11-06. The issuer's own words — QuantLogix does not paraphrase it.
We intend to use the net proceeds from this offering for general corporate purposes, including working capital, operating expenses and capital expenditures.
From vVARDIS Holding AG's Form F-1/A filed with the SEC on 2026-11-06. Quoted from the prospectus.
The audited financial statements for this issuer are in its Form F-1/A filed 2026-11-06. QuantLogix only publishes figures it can read directly from the filing.
The first 6 items of the issuer's “Summary of Risk Factors”, verbatim — the prospectus lists more. From vVARDIS Holding AG's Form F-1/A filed with the SEC on 2026-11-06.
From vVARDIS Holding AG's Form F-1/A filed with the SEC on 2026-11-06. Extraction is deterministic — the same filing always produces the same score; 504k characters of the document were scanned. Technology signals are lexical indicators, not a technical audit. Not investment advice; the debut itself will be this score's first grade.
Deal terms come from the public IPO calendar and change up to pricing — an expected date reads “to be announced” until the underwriters set it, and a range is not a final price. Implied market cap and float are arithmetic on those disclosed terms. Nothing on this page is a forecast or a recommendation.